Substance / Medication

Ganirelix

SNOMED 395728002 UMLS C0073629

Overview

Active Ingredient

ganirelix

RxNorm CUI

35825

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Secondary Meig's syndrome

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

NCT06175832Phase 4Recruiting60 enrolled

Efficacy of Micronized Natural Progesterone Vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

NCT05954962Phase 4Recruiting150 enrolled

Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women

NCT06745466Phase 4Recruiting30 enrolled

To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

NCT03051087Phase 4Completed255 enrolled

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808Phase 4Completed38 enrolled

View all 12 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study.

Han E Jung, Lyu Sang Woo, Kwak In Pyung et al. · J Obstet Gynaecol · 2022

PMID: 35254199RCT

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women.

Messinis Ioannis E, Vanakara Polyxeni, Zavos Apostolos et al. · Fertil Steril · 2010

PMID: 20149361RCT

Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.

Gustofson Robert L, Segars James H, Larsen Frederick W · Hum Reprod · 2006

PMID: 16966348RCT

Correlation of LH level and steroid concentrations in GnRH antagonist protocol: A sub-analysis of Ganirelix phase III study of China.

Li Rong, Gong Fei, Chen Hua et al. · J Gynecol Obstet Hum Reprod · 2022

PMID: 35318120Trial

Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.

Beguería R, García D, Vassena R et al. · Hum Reprod · 2019

PMID: 30927417Trial

A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.

Qiao Jie, Lu Guangxiu, Zhang H W et al. · Gynecol Endocrinol · 2012

PMID: 22429192Trial

Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation.

Bonduelle Maryse, Oberyé Janine, Mannaerts Bernadette et al. · Hum Reprod · 2010

PMID: 20378616Trial

Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.

Wilcox John, Potter Daniel, Moore Marva et al. · Fertil Steril · 2005

PMID: 16009165Trial

Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.

Moon Shin Yong, Ku Seung-Yup, Kim Sun Mie et al. · J Obstet Gynaecol Res · 2005

PMID: 15916659Trial

Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.

Flierman P A, Oberyé J J L, van der Hulst V P M et al. · BJOG · 2005

PMID: 15842290Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ganirelix (substance)
SNOMED CT: 395728002
UMLS CUI: C0073629
RxNorm CUI: 35825

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.